Analysis of Inventory
Inventory Disclosure
Edwards Lifesciences Corp., balance sheet: inventory
US$ in thousands
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
- Raw materials
- The value of raw materials displayed an overall increasing trend from 2017 to 2020, rising from 101,400 thousand US dollars to 136,700 thousand US dollars. However, there was a slight decline in 2021 to 132,800 thousand US dollars, indicating a possible reduction in raw material stock or improved inventory management in that year.
- Work in process
- Work in process inventory showed fluctuations over the period. It increased significantly from 121,100 thousand US dollars in 2017 to 144,800 thousand US dollars in 2018, then declined sharply in 2019 to 121,700 thousand US dollars. A recovery was observed in subsequent years, with an increase to 140,000 thousand in 2020 and further growth to 164,300 thousand in 2021, suggesting variability in production stages or changing manufacturing processes.
- Finished products
- Finished products inventory expanded substantially from 332,400 thousand US dollars in 2017 to 525,600 thousand US dollars in 2020, reflecting strong accumulation of completed goods. In 2021, however, there was a notable decrease to 429,600 thousand US dollars, which may indicate increased sales, product turnover, or strategic inventory reduction.
- Inventories (Total)
- Total inventories grew consistently from 554,900 thousand US dollars in 2017 to a peak of 802,300 thousand US dollars in 2020, implying overall accumulation of stock. This was followed by a reduction in 2021 to 726,700 thousand US dollars, driven primarily by decreases in raw materials and finished products. This pattern suggests an adjustment to inventory levels possibly aligned with market demand or operational efficiency measures.